DiaMedica Therapeutics
DMAC
32 hedge funds and large institutions have $15.1M invested in DiaMedica Therapeutics in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 2 closing their positions.
12,600% more call options, than puts
Call options by funds: $127K | Put options by funds: $1K
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
284% more capital invested
Capital invested by funds: $3.93M → $15.1M (+$11.2M)
28% more funds holding
Funds holding: 25 → 32 (+7)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
3.26% more ownership
Funds ownership: 9.7% → 12.96% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Dallas,
Texas
|
+$789K |
| 2 |
BL
Bleichroeder LP
New York
|
+$714K |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$657K |
| 4 |
First Manhattan
New York
|
+$303K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$41.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$99K |
| 2 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
-$85K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$83.4K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$21K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$8.07K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FDCDDQ
26
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $994 | – | – | – |
|
27
Wells Fargo
San Francisco,
California
| $501 | +$10 | +4 | +4% |
|
|
S
28
SignatureFD
Atlanta,
Georgia
| $108 | +$61 | +25 | New |
|
29
JP Morgan Chase
New York
| $91 | +$51 | +21 | New |
|
30
Osaic Holdings
Scottsdale,
Arizona
| $4 | +$2 | +1 | New |
|
|
31
Renaissance Technologies
New York
| – | -$99K | -64,508 | Closed |
|
|
32
Simplex Trading
Chicago,
Illinois
| – | -$8.07K | -3,324 | -94% |
|
33
UBS Group
Zurich,
Switzerland
| – | -$3.12K | -2,038 | Closed |
|
DMAC Hedge Fund Activity: Q2 2023 in Review
32 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q2 2023, worth a combined $15.1M — up 284% from $3.93M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new DMAC positions and 2 closed out — a net gain of 7 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Paragon Associates & Paragon Associates II Joint Venture, opening a new position worth an estimated $789K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $99K sold.
- 32 institutional investors held DiaMedica Therapeutics (DMAC) as of Q2 2023, up from 25 in Q1 2023.
- Funds reported $15.1M of DiaMedica Therapeutics stock for Q2 2023, up 284% quarter-over-quarter.
- 9 funds opened new DiaMedica Therapeutics positions in Q2 2023 and 2 closed out, a net change of +7 holders.
- The largest DiaMedica Therapeutics buyer in Q2 2023 was Paragon Associates & Paragon Associates II Joint Venture, an estimated $789K added.
- The largest DiaMedica Therapeutics seller in Q2 2023 was Renaissance Technologies, an estimated $99K sold.
Based on aggregated 13F filings for Q2 2023.